# IMROZ (NCT03319667)

> A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03319667
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sanofi
- Conditions: Plasma Cell Myeloma
- Interventions: Isatuximab SAR650984; Bortezomib; Lenalidomide; Dexamethasone
- Enrollment: 475
- Primary outcome: Progression free survival (PFS)

## Commentary we found

- X threads: 89
- YouTube: 84
- Podcasts: 37

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=imroz-nct03319667

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03319667", "email": "<work email>"}; the inbox owner confirms by the emailed link.